A statistical method, Matching-Adjusted Indirect Comparison (MAIC), has been used to evaluate the effectiveness of different PARP inhibitor combinations for treating metastatic castration-resistant prostate cancer (mCRPC).
The study, published on Nature, found that a combination of talazoparib and enzalutamide (TALA + ENZA) may be more effective than other PARP inhibitor combinations, such as olaparib plus abiraterone acetate and niraparib plus abiraterone acetate. TALA + ENZA was found to slow cancer progression, particularly in patients with homologous recombination repair mutations.
The combination also showed a better PSA response compared to olaparib plus abiraterone acetate. However, the article acknowledges the limitations of indirect comparisons and emphasizes the need for further research.